uniQure Earnings Call Transcripts
Fiscal Year 2026
-
Phase I/II data for Huntington's showed significant slowing of disease progression and a strong safety profile, but FDA requires a new phase III trial due to concerns over post hoc analyses. Early results in epilepsy and Fabry programs are promising, with further data and regulatory discussions expected in 2024.
Fiscal Year 2025
-
Full-year 2025 revenue declined to $16.1M, with a strong cash position of $622.5M supporting operations into 2029. AMT-130 for Huntington's disease showed robust 3-year efficacy data, but faces regulatory hurdles as the FDA requires a Phase III sham-controlled trial.
-
Q3 2025 saw strong clinical results for AMT-130 in Huntington's disease, but FDA feedback has delayed the regulatory path. Financials showed increased revenue and a robust cash position, supporting ongoing R&D and commercialization plans.
-
AMT-130 gene therapy achieved a 75% reduction in Huntington's disease progression and a 60% slowing in functional decline at 36 months, with robust biomarker and safety data. The therapy is moving toward regulatory submission, with strong expert support and significant commercial potential.
-
Advanced AMT-130 for Huntington's disease with FDA breakthrough designation and regulatory alignment for a 2026 BLA submission. Q2 revenue declined year-over-year, but cash reserves increased, supporting a robust pipeline and commercial preparations.
-
Alignment with FDA enables a clear regulatory path for AMT-130, leveraging robust manufacturing and statistical methodologies. The primary efficacy analysis will use Enroll-HD as an external control, with top-line data expected in Q3 and a BLA submission planned for Q1 2026.
-
Q1 2025 saw continued pipeline progress, highlighted by AMT-130's FDA Breakthrough Therapy Designation and strong cash reserves of $409 million. Revenue declined year-over-year due to the Lexington facility divestiture, but the company remains on track for key data readouts and a planned BLA submission for Huntington's disease.
-
Multiple gene therapy programs are advancing, with Huntington's disease leading and a BLA submission targeted following positive FDA feedback. Initial data for Fabry and SOD1 ALS are expected in 2024–2025, supported by strong cash reserves and a robust launch strategy.
-
Significant progress was made in the HD program, including FDA alignment on endpoints and manufacturing, with AMT-130 showing strong efficacy and safety data. The pipeline advanced with new trials in Fabry, epilepsy, and ALS, and commercial plans focus on a large, urgent HD market.
-
Favorable FDA feedback supports accelerated approval for the Huntington's gene therapy, with key regulatory meetings and process validation activities planned in the coming months. The pipeline includes Fabry, SOD1-ALS, and TLE, with a focus on leveraging existing gene therapy platforms.
Fiscal Year 2024
-
Alignment with the FDA enables an accelerated approval pathway for AMT-130 in Huntington's disease, leveraging robust phase I/II data and eliminating the need for an additional registration trial. Key endpoints include cUHDRS and CSF NfL reduction, with BLA submission preparations underway.
-
Significant progress was made in advancing the HD program, achieving RMAT designation, and initiating new clinical studies in epilepsy, ALS, and Fabry disease. Two-year data showed meaningful slowing of HD progression, and regulatory engagement with the FDA is ongoing, with key milestones expected next year.
-
A late November FDA meeting will set the stage for regulatory alignment, with key updates expected mid-2025. Clinical data in Huntington’s disease show meaningful biomarker and functional improvements, while early intervention and streamlined procedures are prioritized. Fabry and TLE programs are advancing, with regulatory flexibility seen as beneficial.
-
The company is advancing four CNS-focused gene therapy programs, with AMT-260 for temporal lobe epilepsy showing strong preclinical results and a rapid clinical proof-of-concept path. Huntington’s disease data reveal slowed progression and biomarker improvements, with regulatory engagement underway.
-
The discussion highlighted a robust AAV gene therapy pipeline, with a focus on Huntington's disease and regulatory strategies leveraging long-term clinical outcomes. Progress continues in epilepsy, ALS, and Fabry programs, each differentiated by vector choice and delivery approach.
-
Interim phase I/II data for AMT-130 in Huntington's disease show statistically significant, dose-dependent slowing of disease progression and unprecedented reductions in neurodegeneration biomarkers at 24 months. The therapy remains well tolerated, with regulatory discussions and further analyses planned.